Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes (Q37623110)

21 August 2017

1 reference

title

Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes (English)

1 reference

21 August 2017

Robert S Rosenson

1

1 reference

PubMed ID

19863869

21 August 2017

Michael H Gelb

series ordinal

2

1 reference

21 August 2017

1 November 2009

1 reference

Current cardiology reports

21 August 2017

1 reference

21 August 2017

11

1 reference

21 August 2017

6

1 reference

21 August 2017

445-451

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-009-0064-2

21 August 2017

0 references

cites work

Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Akt as a mediator of secretory phospholipase A2 receptor-involved inducible nitric oxide synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-009-0064-2

Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human

21 January 2018

1 reference

12 December 2020

On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids

1 reference

12 December 2020

Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans.

1 reference

12 December 2020

Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner

1 reference

12 December 2020

Glycogen synthase kinase-3beta negatively regulates group IIA phospholipase A2 expression in human aortic smooth muscle and HepG2 hepatoma cells

1 reference

12 December 2020

Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model

1 reference

12 December 2020

Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate

1 reference

12 December 2020

Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice

1 reference

12 December 2020

Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.

1 reference

12 December 2020

Phospholipase A2 biochemistry

1 reference

12 December 2020

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

1 reference

12 December 2020

Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.

1 reference

12 December 2020

Potential involvement of type II phospholipase A2 in atherosclerosis

1 reference

12 December 2020

Purification and characterization of a membrane-associated phospholipase A2 from rat spleen. Its comparison with a cytosolic phospholipase A2 S-1

1 reference

12 December 2020

Biochemistry and physiology of mammalian secreted phospholipases A2.

1 reference

12 December 2020

Cloning and recombinant expression of a structurally novel human secreted phospholipase A2

1 reference

12 December 2020

Alterations in the physiochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study

1 reference

12 December 2020

Expression of secretory phospholipase A2s in human atherosclerosis development

1 reference

12 December 2020

Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation

1 reference

12 December 2020

Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions

1 reference

12 December 2020

Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells

1 reference

12 December 2020

Crystal structure of human group X secreted phospholipase A2. Electrostatically neutral interfacial surface targets zwitterionic membranes

1 reference

12 December 2020

The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

1 reference

12 December 2020

Group X secretory phospholipase A2 can induce arachidonic acid release and eicosanoid production without activation of cytosolic phospholipase A2 alpha

1 reference

12 December 2020

Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin

1 reference

12 December 2020

Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells

1 reference

12 December 2020

Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells.

1 reference

12 December 2020

Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice

1 reference

12 December 2020

Identification of a soluble form phospholipase A2 receptor as a circulating endogenous inhibitor for secretory phospholipase A2

1 reference

12 December 2020

Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2.

1 reference

12 December 2020

Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress

1 reference

12 December 2020

Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A2

1 reference

12 December 2020

Biology of secretory phospholipase A2.

1 reference

12 December 2020

Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I

1 reference

12 December 2020

The antibacterial properties of secreted phospholipases A2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall

1 reference

12 December 2020

Lipolysis of LDL by Human Secretory Phospholipase A 2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans

1 reference

12 December 2020

Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans.

1 reference

12 December 2020

Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet

1 reference

12 December 2020

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

1 reference

12 December 2020

Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.

1 reference

12 December 2020

Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages

1 reference

12 December 2020

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice

1 reference

12 December 2020

Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins

1 reference

12 December 2020

Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans

1 reference

12 December 2020

Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway

1 reference

12 December 2020

10.1007/S11886-009-0064-2

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19863869